References
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. https://doi.org/10.3322/caac.20073
- Rigas JR. Do newer chemotherapeutic agents improve survival in non-small cell lung cancer? Semin Oncol 1998;25(3 Suppl 8):5-9.
- Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001;12 Suppl 1:S21-4. https://doi.org/10.1097/00001813-200107003-00005
- Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74. https://doi.org/10.1146/annurev.med.48.1.353
- Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86. https://doi.org/10.1038/sj.onc.1207233
- Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
- Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
- Lee LF, Li G, Templeton DJ, Ting JP. Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60. https://doi.org/10.1074/jbc.273.43.28253
- Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR, Chiles TC. Transient stimulation of the c-Jun-NH2-terminal kinase/ activator protein 1 pathway and inhibition of extracellular signal- regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 1998;58:241-7
- Mhaidat NM, Zhang XD, Jiang CC, Hersey P. Docetaxelinduced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 2007;13:1308-14. https://doi.org/10.1158/1078-0432.CCR-06-2216
- Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther 2007;6:752-61 https://doi.org/10.1158/1535-7163.MCT-06-0564
- Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005;23:422-31 https://doi.org/10.1200/JCO.2005.09.078
- Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life 2001;52:35-41. https://doi.org/10.1080/15216540252774748
- Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999;145:127-32. https://doi.org/10.1016/S0304-3835(99)00243-8
- Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 2000;156:27-35. https://doi.org/10.1016/S0304-3835(00)00434-1
- Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 2001;21:2085-90.
- Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004;111:514-21. https://doi.org/10.1002/ijc.20294
- Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 2003;19:285-98. https://doi.org/10.1023/B:CBTO.0000004952.07979.3d
- Chang JW, Lee SH, Jeong JY, Chae HZ, Kim YC, Park ZY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 2005;579:2873-7. https://doi.org/10.1016/j.febslet.2005.04.028
- Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 2006;64:581-91. https://doi.org/10.1016/j.ijrobp.2005.10.012
- Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res 2007;13:3875-82. https://doi.org/10.1158/1078-0432.CCR-06-2893
- Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 2008;14:2326-33. https://doi.org/10.1158/1078-0432.CCR-07-4457
- Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 2009;7:1543-52. https://doi.org/10.1158/1541-7786.MCR-08-0546
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
- Suhara T, Kim HS, Kirshenbaum LA, Walsh K. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 2002;22:680-91. https://doi.org/10.1128/MCB.22.2.680-691.2002
- Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000;10:1201-4. https://doi.org/10.1016/S0960-9822(00)00728-4
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. https://doi.org/10.1056/NEJMoa040720
- Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, et al. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005;65:141-50. https://doi.org/10.1002/pros.20246
- Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-91. https://doi.org/10.1016/S1097-2765(00)80157-4
- Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 2006;12(20 Pt 1):6153-60. https://doi.org/10.1158/1078-0432.CCR-06-0443
- Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 2008;261:108-19. https://doi.org/10.1016/j.canlet.2007.11.022
- Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E, Oya M. Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol 2011;185:2376-81. https://doi.org/10.1016/j.juro.2011.02.016
- Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 1999;96:7421-6. https://doi.org/10.1073/pnas.96.13.7421
- Kops GJ, Burgering BM. Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med (Berl) 1999;77:656-65. https://doi.org/10.1007/s001099900050
- Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68. https://doi.org/10.1016/S0092-8674(00)80595-4
- Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002;277:47928-37. https://doi.org/10.1074/jbc.M207509200
- Lee YJ, Park MY, Kang YA, Kwon SY, Yoon HI, Lee JH, et al. Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib of IGF-1R blockade. Tuberc Respir Dis 2007;63:42-51. https://doi.org/10.4046/trd.2007.63.1.42
Cited by
- Why high cholesterol levels help hematological malignancies: role of nuclear lipid microdomains vol.15, pp.None, 2013, https://doi.org/10.1186/s12944-015-0175-2
- The prognostic values of the peroxiredoxins family in ovarian cancer vol.38, pp.5, 2013, https://doi.org/10.1042/bsr20180667
- Catalytic and Signaling Role of Peroxiredoxins in Carcinogenesis vol.84, pp.2, 2013, https://doi.org/10.1134/s0006297919020019
- Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT vol.19, pp.1, 2019, https://doi.org/10.1186/s12885-019-6046-x